



Amendment
Serial No. 10/786,016
Attorney Docket No. 021310A

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions of claims in the application:

1-23. (Canceled)

24. (Currently amended): A composition, comprising:

_____ at least one of an interleukin 18 inhibitor and/or an interleukin 2 inhibitor, and a pharmaceutical additive, so that the composition is in a form suitable for administration to humans.

25-31. (Canceled)

32. (New): The composition of claim 24, which is a dose containing from 0.1 to 1,000 mg of the inhibitor or inhibitors.

33. (New): The composition of claim 32, which is in a form selected from the group consisting of tablets, capsules, granules, fine granules, powders, isotonic agent solution, soluble freeze-dried preparation, sodium chloride suspension for inhalation, and combinations thereof.

34. (New): A composition comprising at least one of an isolated, purified, or non-naturally occurring interleukin 18 inhibitor and/or an isolated, purified, or non-naturally occurring interleukin 2 inhibitor.

35. (New): The composition of claim 34, further comprising a pharmaceutical additive, so that the composition is in a form suitable for administration to humans.

36. (New): The composition of claim 35, which is a dose containing from 0.1 to 1,000 mg of the inhibitor or inhibitors.

37. (New): The composition of claim 36, which is in a form selected from the group consisting of tablets, capsules, granules, fine granules, powders, isotonic agent solution, soluble freeze-dried preparation, sodium chloride suspension for inhalation, and combinations thereof.

38. (New): The composition of claim 34, wherein the at least one inhibitor comprises an interleukin 18 inhibitor.

39. (New): The composition of claim 34, wherein the at least one inhibitor comprises an interleukin 2 inhibitor.

40. (New): The composition of claim 38, wherein the composition comprises an interleukin 18 inhibitor which is a monoclonal antibody specific for interleukin 18 or a receptor of interleukin 18.

41. (New): The composition of claim 38, wherein the composition comprises an interleukin 18 inhibitor which is a substance which inhibits conversion of a precursor of interleukin 18 into an activated one.

42. (New): The composition of claim 38, wherein the composition comprises an interleukin 18 inhibitor which is an inhibitor of cysteine protease.

43. (New): The composition of claim 38, wherein the composition comprises an interleukin 18 inhibitor which is an interleukin 1 .beta.-converting enzyme inhibitor.

44. (New): The composition of claim 38, wherein the composition comprises an interleukin 18 inhibitor which is an interleukin 18-binding protein.

45. (New): The composition of claim 39, wherein the interleukin 2 inhibitor is a monoclonal antibody specific for interleukin 2 or a receptor of interleukin 2.

46. (New): The composition of claim 39, wherein the composition comprises an interleukin 2 inhibitor which is a substance which acts as an antagonist of interleukin 2.

47. (New): The composition of claim 39, wherein the composition comprises an interleukin 2 inhibitor which is an interleukin 2-diphtheria toxin conjugate.

48. (New): The composition of claim 39, wherein the composition comprises an interleukin 2 inhibitor which is an antibody or ligand bound to alpha chain, beta chain and/or gamma chain subunits of the interleukin 2 receptor.

49. (New): The composition of claim 24, wherein the composition comprises an interleukin 18 inhibitor which is selected from the group consisting of a substance which inhibits conversion of a precursor of interleukin 18 into an activated one, an inhibitor of cysteine protease, an interleukin 1 .beta.-converting enzyme inhibitor, and an interleukin 18-binding protein.

50. (New): The composition of claim 24, wherein the composition comprises an interleukin 2 inhibitor which is selected from the group consisting of a substance which acts as an antagonist of interleukin 2, an interleukin 2-diphtheria toxin conjugate, and an antibody or

Amendment
Serial No. 10/786,016
Attorney Docket No. 021310A

ligand bound to alpha chain, beta chain and/or gamma chain subunits of the interleukin 2
receptor.